STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Sponsor: NYU Langone Health
Terminated
Study is permanently closed to enrollment .Collection of private identifiable information is complete Analysis of private identifiable information is complete
Listed as NCT01663571, this observational or N/A phase trial focuses on Cutaneous T Cell Lymphoma and remains terminated or withdrawn. Sponsored by NYU Langone Health, it has been updated 13 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 8 earlier versions
-
Jun 2019 — Nov 2020 [monthly]
Terminated
-
Oct 2018 — Jun 2019 [monthly]
Terminated
-
Jun 2018 — Oct 2018 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Aug 2017 — Nov 2017 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .